UK regulator expands Imcivree approval to hypothalamic obesity
Go back to UK regulator expands Imcivree approval to hypothalamic obesity| (NASDAQ: RYTM) | Delayed: 88.92 -1.98 (2.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.90 | 52 Week High | $ | |||
| Open | $89.88 | 52 Week Low | $ | |||
| Day High | $90.21 | P/E | N/A | |||
| Day Low | $88.56 | EPS | $ | |||
| Volume | 232,371 | |||||



